Document is current
Any future updates will be listed below
-
Authors
Vaiana, Alexandra M.
Chen, Yidong
Gelfond, Jonathan
Johnson-Pais, Teresa L.
Leach, Robin J.
Ramamurthy, Chethan
Thompson, Ian M.
Morilak, David A. https://orcid.org/0000-0001-6689-6258
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 CA224672, P30 CA054174, S10 OD021805, UL TR002645)
Cancer Prevention and Research Institute of Texas (RP180055, RP170345, RP160732, RP170345)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Quincy and Estine Lee Endowment Fund; Mays Cancer Center, UT Health San Antonio
- License Information
-
More Information
Article History
Received: 27 January 2023
Revised: 15 September 2023
Accepted: 20 September 2023
First Online: 3 October 2023
Competing interests
: Vortioxetine was provided by H. Lundbeck A/S, which had no input into the design or conduct of the study, analysis or interpretation of the data, and no role in the decision to publish or in the writing of the manuscript. The authors declare no competing interests.
: The Institutional Animal Care and Use Committee (IACUC) of the University of Texas Health, San Antonio, reviewed and approved all research procedures. All experiments were compliant with the ethical standards of the National Institutes of Health as specified in the Guide for the Care and Use of Laboratory Animals.
